The SENSE study, a Phase 1/2a clinical trial evaluating NG101, has reached a key milestone with the completion of patient dosing. This study focuses on assessing the safety and bioactivity of the gene therapy delivered via subretinal injection.
Read Original Article (English)
*Note: This link will redirect you to the original source in English.